Search
Viomycin
go.drugbank.com/drugs/DB06827ApprovedViomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was deri...
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesRhizopus arrhizus var. arrhizus
go.drugbank.com/drugs/DB10441ApprovedRhizopus arrhizus var. arrhizus is a fungus which can provoke allergic reactions. Rhizopus arrhizus var. arrhizus extract is used in allergenic testing.
Puccinia striiformis var. striiformis
go.drugbank.com/drugs/DB10937ApprovedPuccinia striiformis var. striiformis is a fungus which can provoke allergic reactions. Puccinia striiformis var. striiformis extract is used in allergenic testing.
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalThus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Diethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Ann...
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnEflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. … [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[L13380] As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-oneSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub … [L45300,L45315] In September 2024, it was granted full approval for an expanded indication.
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates